Hypoxia-inducible factor-1 (HIF-1): A potential target for intervention in ocular neovascular diseases

Current Drug Targets

Volumn 14, Issue 8, 2013, Pages 919-935

  Vadlapatla, Ramya Krishna ^a   Vadlapudi, Aswani Dutt ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Age related macular degeneration; Diabetic retinopathy; Hypoxia signaling; Hypoxia inducible factor 1 (HIF 1); Ocular neovascularization; Retinopathy of prematurity

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [BIS (2 CHLOROETHYL) OXIDOAMINO] PHENYLALANINE; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; AFLIBERCEPT; APIGENIN; BEVACIZUMAB; DEGUELIN; DIGOXIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GELDANAMYCIN; GENISTEIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LEUCENTIS; NELFINAVIR; PEGAPTANIB; RANIBIZUMAB; RAPAMYCIN; RESVERATROL; ROMIDEPSIN; SILIBININ; SORAFENIB; TEMSIROLIMUS; TOPOTECAN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEGF TRAP EYE; VORINOSTAT; WORTMANNIN;

ACETYLATION; ANGIOGENESIS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DIABETIC RETINOPATHY; DNA BINDING; ENZYME DEGRADATION; ENZYME REGULATION; EYE DISEASE; GLAUCOMA; HUMAN; HYDROXYLATION; NONHUMAN; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; RNA INTERFERENCE; TRANSACTIVATION; UBIQUITINATION; VEIN OCCLUSION;

AGED; ANIMALS; CELL HYPOXIA; CHILD; EYE DISEASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MOLECULAR TARGETED THERAPY; OXYGEN; RETINAL DISEASES; SIGNAL TRANSDUCTION;

EID: 84881365842     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990015     Document Type: Review

References (250)

1. Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2010; 2(3): 336-61.
2. Semenza GL. Life with oxygen. Science 2007; 318(5847): 62-4.
3. Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 2004; 18(18): 2183-94.
4. Lopez-Barneo J, Pardal R, Ortega-Saenz P. Cellular mechanism of oxygen sensing. Annu Rev Physiol 2001; 63: 259-87.
5. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxiainducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88(13): 5680-4.
6. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242(4884): 1412-5.
7. Loenarz C, Coleman ML, Boleininger A, et al. The hypoxiainducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep 2011; 12(1): 63-70.
8. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92(12): 5510-4.
9. Reyes H, Reisz-Porszasz S, Hankinson O. Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 1992; 256(5060): 1193-5.
10. Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J 2012; 31(11): 2448-60.
11. Li Y, Ye D. Cancer therapy by targeting hypoxia-inducible factor- 1. Curr Cancer Drug Targets 2010; 10(7): 782-96.
12. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271(30): 17771-8.
13. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxiainducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95(14): 7987-92.
14. Ruas JL, Poellinger L, Pereira T. Functional analysis of hypoxiainducible factor-1 alpha-mediated transactivation. Identification of amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein. J Biol Chem 2002; 277(41): 38723-30.
15. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997; 272(31): 19253-60.
16. Kallio PJ, Okamoto K, O'Brien S, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 1998; 17(22): 6573-86.
17. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 1998; 12(21): 3320-4.
18. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94(9): 4273-8.
19. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11(1): 72-82.
20. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 2001; 287(4): 808-13.
21. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998; 7(3): 205-13.
22. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002; 277(36): 32405-8.
23. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414(6863): 550-4.
24. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998; 92(7): 2260-8.
25. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997; 94(11): 5667-72.
26. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 2005; 17(1): 1-9.
27. Welsh SJ, Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 2003; 3(6): 391-405.
28. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292(5516): 464-8.
29. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292(5516): 468-72.
30. Masson N, Ratcliffe PJ. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J Cell Sci 2003; 116(Pt 15): 3041-9.
31. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxiainducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20(18): 5197-206.
32. Srinivas V, Zhang LP, Zhu XH, Caro J. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins. Biochem Biophys Res Commun 1999; 260(2): 557-61.
33. Huang J, Zhao Q, Mooney SM, Lee FS. Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J Biol Chem 2002; 277(42): 39792-800.
34. Schofield CJ, Zhang Z. Structural and mechanistic studies on 2- oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 1999; 9(6): 722-31.
35. Bruick RK, McKnight SL. A conserved family of prolyl-4- hydroxylases that modify HIF. Science 2001; 294(5545): 1337-40.
36. Lando D, Gorman JJ, Whitelaw ML, Peet DJ. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem 2003; 270(5): 781-90.
37. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93(25): 14765-70.
38. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107(1): 43-54.
39. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22(16): 4082-90.
40. Metzen E, Berchner-Pfannschmidt U, Stengel P, et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 2003; 116(Pt 7): 1319-26.
41. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002; 417(6892): 975-8.
42. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG, Jr., Pavletich NP. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 2002; 296(5574): 1886-9.
43. Ivan M, Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 2001; 11(1): 27-34.
44. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000; 97(19): 10430-5.
45. Groulx I, Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol 2002; 22(15): 5319-36.
46. Berra E, Roux D, Richard DE, Pouyssegur J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep 2001; 2(7): 615-20.
47. Yu F, White SB, Zhao Q, Lee FS. Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel- Lindau tumor suppressor protein. Cancer Res 2001; 61(10): 4136-42.
48. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Upregulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel- Lindau tumor suppressor gene loss of function. Oncogene 2000; 19(48): 5435-43.
49. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275(33): 25733-41.
50. Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111(5): 709-20.
51. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7(4): 437-43.
52. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19(16): 4298-309.
53. Sang N, Fang J, Srinivas V, Leshchinsky I, Caro J. Carboxylterminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol Cell Biol 2002; 22(9): 2984-92.
54. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295(5556): 858-61.
55. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16(12): 1466-71.
56. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002; 277(29): 26351-5.
57. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001; 15(20): 2675-86.
58. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, et al. Structural basis for recruitment of CBP/p300 by hypoxia inducible factor-1 alpha. Proc Natl Acad Sci USA 2002; 99(8): 5367-72.
59. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE. Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA 2002; 99(8): 5271-6.
60. Minet E, Michel G, Mottet D, Raes M, Michiels C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med 2001; 31(7): 847-55.
61. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcomaassociated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000; 60(17): 4873-80.
62. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 274(46): 32631-7.
63. Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxiainducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001; 20(41): 5779-88.
64. Hur E, Chang KY, Lee E, Lee SK, Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxiainducible factor-1alpha. Mol Pharmacol 2001; 59(5): 1216-24.
65. Gradin K, Takasaki C, Fujii-Kuriyama Y, Sogawa K. The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine. J Biol Chem 2002; 277(26): 23508-14.
66. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; 2005(306): re12.
67. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 1996; 271(50): 32253-9.
68. Pugh CW, Tan CC, Jones RW, Ratcliffe PJ. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. Proc Natl Acad Sci USA 1991; 88(23): 10553-7.
69. Barnhart BC, Simon MC. Metastasis and stem cell pathways. Cancer Metastasis Rev 2007; 26(2): 261-71.
70. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007; 26(2): 319-31.
71. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007; 26(2): 333-9.
72. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007; 26(2): 241-8.
73. Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 2007; 26(2): 249-60.
74. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26(2): 299-310.
75. Lukashev D, Ohta A, Sitkovsky M. Hypoxia-dependent antiinflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev 2007; 26(2): 273-9.
76. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67(2): 563-72.
77. LeCouter J, Kowalski J, Foster J, et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001; 412(6850): 877-84.
78. Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor- 1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 2000; 105(5): 577-87.
79. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270(22): 13333-40.
80. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997; 272(38): 23659-67.
81. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97(16): 9082-7.
82. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999; 59(16): 3915-8.
83. Tazuke SI, Mazure NM, Sugawara J, et al. Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci USA 1998; 95(17): 10188-93.
84. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63(5): 1138-43.
85. Lofstedt T, Jogi A, Sigvardsson M, et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 2004; 279(38): 39223-31.
86. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279(23): 24218-25.
87. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62(12): 3387-94.
88. Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002; 277(45): 42953-7.
89. Koshiji M, To KK, Hammer S, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 2005; 17(6): 793-803.
90. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12(2): 149-62.
91. Wood SM, Wiesener MS, Yeates KM, et al. Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alphadependent and -independent hypoxia-inducible gene expression. J Biol Chem 1998; 273(14): 8360-8.
92. Hogenesch JB, Gu YZ, Moran SM, et al. The basic helix-loophelix- PAS protein MOP9 is a brain-specific heterodimeric partner of circadian and hypoxia factors. J Neurosci 2000; 20(13): RC83.
93. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxiainducible factor 1. J Biol Chem 1994; 269(38): 23757-63.
94. Fu L, Chen L, Yang J, Ye T, Chen Y, Fang J. HIF-1alpha-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis 2012; 33(9): 1664-73.
95. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxiainducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000; 275(28): 21048-54.
96. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygenregulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997; 272(32): 20055-62.
97. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 1999; 274(34): 24147-52.
98. Takahashi Y, Takahashi S, Shiga Y, Yoshimi T, Miura T. Hypoxic induction of prolyl 4-hydroxylase alpha (I) in cultured cells. J Biol Chem 2000; 275(19): 14139-46.
99. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 2002; 90(7): 784-91.
100. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999; 94(12): 4177-85.
101. Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC. Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell 2005; 16(4): 1901-12.
102. Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006; 86(12): 1221-32.
103. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60(24): 7075-83.
104. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sato Y. Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 2001; 289(1): 39-43.
105. Eckhart AD, Yang N, Xin X, Faber JE. Characterization of the alpha1B-adrenergic receptor gene promoter region and hypoxia regulatory elements in vascular smooth muscle. Proc Natl Acad Sci USA 1997; 94(17): 9487-92.
106. Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 1998; 273(28): 17787-92.
107. Hu J, Discher DJ, Bishopric NH, Webster KA. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxiainducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 1998; 245(3): 894-9.
108. Lee PJ, Jiang BH, Chin BY, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 1997; 272(9): 5375-81.
109. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995; 182(6): 1683-93.
110. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49(3): 507-21.
111. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001; 11(1): 35-40.
112. Berra E, Milanini J, Richard DE, et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000; 60(8): 1171-8.
113. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16(9): 4604-13.
114. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76(3): 839-85.
115. Josko J, Gwozdz B, Jedrzejowska-Szypulka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000; 6(5): 1047-52.
116. Harris AL. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist 2000; 5 Suppl 1: 32-6.
117. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13(1): 9-22.
118. Nguyen SV, Claycomb WC. Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun 1999; 265(2): 382-6.
119. Lima e Silva R, Shen J, Hackett SF, et al. The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J 2007; 21(12): 3219-30.
120. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44(7): 3186-93.
121. Seo MS, Okamoto N, Vinores MA, et al. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am J Pathol 2000; 157(3): 995-1005.
122. Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 2000; 184(3): 275-84.
123. Ames A, 3rd. Energy requirements of CNS cells as related to their function and to their vulnerability to ischemia: a commentary based on studies on retina. Can J Physiol Pharmacol 1992; 70 Suppl: S158-64.
124. Campochiaro PA. Ocular neovascularization. J Mol Med (Berl) 2013; 91(3): 311-21.
125. Caprara C, Grimm C. From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res 2012; 31(1): 89-119.
126. Sung CH, Chuang JZ. The cell biology of vision. J Cell Biol 2010; 190(6): 953-63.
127. Baccus SA. Timing and computation in inner retinal circuitry. Annu Rev Physiol 2007; 69: 271-90.
128. Okawa H, Sampath AP, Laughlin SB, Fain GL. ATP consumption by mammalian rod photoreceptors in darkness and in light. Curr Biol 2008; 18(24): 1917-21.
129. Stone J, van Driel D, Valter K, Rees S, Provis J. The locations of mitochondria in mammalian photoreceptors: relation to retinal vasculature. Brain Res 2008; 1189: 58-69.
130. Flammer J, Mozaffarieh M. Autoregulation, A balancing act between supply and demand. Can J Ophthalmol 2008; 43(3): 317-21.
131. Pournaras CJ, Rungger-Brandle E, Riva CE, Hardarson SH, Stefansson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res 2008; 27(3): 284-330.
132. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol 2004; 48(8-9): 1045-58.
133. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002; 86(7): 716-22.
134. Ferris FL, 3rd, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999; 341(9): 667-78.
135. Crawford TN, Alfaro DV, 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009; 5(1): 8-13.
136. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-7.
137. Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina 2006; 26(6 Suppl): S71-9.
138. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev 2011; 7(5): 291-304.
139. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2006; 38(5-6): 752-65.
140. Engerman RL, Kern TS. Retinopathy in animal models of diabetes. Diabetes Metab Rev 1995; 11(2): 109-20.
141. Stitt AW, Anderson HR, Gardiner TA, Archer DB. Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br J Ophthalmol 1994; 78(2): 133-7.
142. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulindependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996; 37(5): 886-97.
143. Josifova T, Plestina-Borjan I, Henrich PB. Proliferative diabetic retinopathy: predictive and preventive measures at hypoxia induced retinal changes. The EPMA journal 2010; 1(1): 73-7.
144. Morello CM. Etiology and natural history of diabetic retinopathy: an overview. Am J Health Syst Pharm 2007; 64(17 Suppl 12): S3-7.
145. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007; 298(8): 902-16.
146. Watkins PJ. Retinopathy. BMJ 2003; 326(7395): 924-6.
147. Holekamp NM, Shui YB, Beebe D. Lower intraocular oxygen tension in diabetic patients: possible contribution to decreased incidence of nuclear sclerotic cataract. Am J Ophthalmol 2006; 141(6): 1027-32.
148. Lim JI, Spee C, Hinton DR. A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 2010; 30(9): 1472-8.
149. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxiainducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2007; 91(6): 822-6.
150. Lin M, Chen Y, Jin J, et al. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells. Diabetologia 2011; 54(6): 1554-66.
151. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84(2): 77-82.
152. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol 2003; 8(6): 469-73.
153. Kuriyama H, Waki M, Nakagawa M, Tsuda M. Involvement of oxygen free radicals in experimental retinal ischemia and the selective vulnerability of retinal damage. Ophthalmic Res 2001; 33(4): 196-202.
154. Hardy P, Dumont I, Bhattacharya M, et al. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res 2000; 47(3): 489-509.
155. Hardy P, Abran D, Li DY, Fernandez H, Varma DR, Chemtob S. Free radicals in retinal and choroidal blood flow autoregulation in the piglet: interaction with prostaglandins. Invest Ophthalmol Vis Sci 1994; 35(2): 580-91.
156. Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992; 326(16): 1050-4.
157. Sapieha P, Joyal JS, Rivera JC, et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest 2010; 120(9): 3022-32.
158. Kermorvant-Duchemin E, Sapieha P, Sirinyan M, et al. Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. Doc Ophthalmol 2010; 120(1): 51-60.
159. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 2008; 49(12): 5177-82.
160. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007; 10(2): 133-40.
161. Mowat FM, Luhmann UF, Smith AJ, et al. HIF-1alpha and HIF- 2alpha are differentially activated in distinct cell populations in retinal ischaemia. PloS one 2010; 5(6): e11103.
162. Jiang J, Xia XB, Xu HZ, et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol 2009; 218(1): 66-74.
163. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 2006; 38(7): 450-71.
164. Adams MK, Simpson JA, Aung KZ, Makeyeva GA, Giles GG, English DR, et al. Abdominal obesity and age-related macular degeneration. Am J Epidemiol 2011; 173(11): 1246-55.
165. Reynolds R, Rosner B, Seddon JM. Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration. Ophthalmology 2010; 117(10): 1989-95.
166. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of agerelated macular degeneration and associated risk factors. Arch Ophthalmol 2010; 128(6): 750-8.
167. Tolppanen AM, Nevalainen T, Kolehmainen M, et al. Single nucleotide polymorphisms of the tenomodulin gene (TNMD) in age-related macular degeneration. Mol Vis 2009; 15: 762-70.
168. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003; 44(9): 3771-7.
169. Cook HL, Patel PJ, Tufail A. Age-related macular degeneration: diagnosis and management. Br Med Bull 2008; 85: 127-49.
170. Algvere PV, Seregard S. Drusen maculopathy: a risk factor for AMD. Can we prevent visual loss? Acta Ophthalmol Scand 2003; 81(5): 427-9.
171. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Agerelated macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48(3): 257-93.
172. Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med 2012; 33(4): 295-317.
173. Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med 2009; 102(2): 56-61.
174. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006; 51(2): 137-52.
175. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45(2): 115-34.
176. Arjamaa O, Nikinmaa M, Salminen A, Kaarniranta K. Regulatory role of HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD). Ageing research reviews 2009; 8(4): 349-58.
177. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 2008; 586(Pt 17): 4055-9.
178. Metelitsina TI, Grunwald JE, DuPont JC, Ying GS, Brucker AJ, Dunaief JL. Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49(1): 358-63.
179. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46(3): 1033-8.
180. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004; 242(1): 91-101.
181. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol 2008; 217(3): 674-85.
182. Frede S, Berchner-Pfannschmidt U, Fandrey J. Regulation of hypoxia-inducible factors during inflammation. Methods Enzymol 2007; 435: 405-19.
183. Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, Kent D. Expression of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular membranes. Graefes Arch Clin Exp Ophthalmol 2009; 247(10): 1361-7.
184. Inoue Y, Yanagi Y, Matsuura K, Takahashi H, Tamaki Y, Araie M. Expression of hypoxia-inducible factor 1alpha and 2alpha in choroidal neovascular membranes associated with age-related macular degeneration. Br J Ophthalmol 2007; 91(12): 1720-1.
185. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90(3): 262-7.
186. Liu Y, Allingham RR. Molecular genetics in glaucoma. Exp Eye Res 2011; 93(4): 331-9.
187. Quigley HA. Glaucoma. Lancet 2011; 377(9774): 1367-77.
188. Flammer J, Orgul S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002; 21(4): 359-93.
189. Osborne NN, Melena J, Chidlow G, Wood JP. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001; 85(10): 1252-9.
190. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol 2004; 122(9): 1348-56.
191. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40(3): 352-68.
192. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000; 156(4): 1337-44.
193. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998; 105(2): 232-7.
194. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22): 1480-7.
195. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25(4): 581-611.
196. Famiglietti EV, Stopa EG, McGookin ED, Song P, LeBlanc V, Streeten BW. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res 2003; 969(1-2): 195-204.
197. Takagi H, King GL, Aiello LP. Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 1996; 45(8): 1016-23.
198. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113(12): 1538-44.
199. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 1995; 44(1): 98-103.
200. Kimoto K, Kubota T. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol 2012; 2012: 852183.
201. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56(2): 95-113.
202. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 2011; 12(2): 173-81.
203. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye 2008; 22(10): 1330-6.
204. Quaggin SE. Turning a blind eye to anti-VEGF toxicities. J Clin Invest 2012; 122(11): 3849-51.
205. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 2012; 122(11): 4213-7.
206. Terzuoli E, Puppo M, Rapisarda A, et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res 2010; 70(17): 6837-48.
207. Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008; 7(11): 3598-608.
208. Lin M, Hu Y, Chen Y, et al. Impacts of hypoxia-inducible factor-1 knockout in the retinal pigment epithelium on choroidal neovascularization. Invest Ophthalmol Vis Sci 2012; 53(10): 6197-206.
209. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105(50): 19579-86.
210. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor- 1alpha. Mol Cancer Ther 2008; 7(1): 90-100.
211. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62(15): 4316-24.
212. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1- dependent mechanisms. Cancer Res 2006; 66(6): 3197-204.
213. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS, Hines OJ. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 2004; 100(1): 201-10.
214. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxiainducible factor 1. Cell Growth Differ 2001; 12(7): 363-9.
215. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006; 66(18): 9252-9.
216. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor- 1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 2005; 4(10): 1465-74.
217. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13(14): 4261-70.
218. Wang W, Jia WD, Xu GL, et al. Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci 2009; 54(10): 2128-36.
219. Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009; 28(3): 313-24.
220. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006; 8(5): 394-401.
221. Kumar SM, Yu H, Edwards R, et al. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 2007; 67(7): 3177-84.
222. Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis 2007; 28(4): 858-64.
223. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 2009; 69(4): 1624-32.
224. Alqawi O, Moghaddas M, Singh G. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells. Prostate Cancer Prostatic Dis 2006; 9(2): 126-35.
225. Mie Lee Y, Kim SH, Kim HS, et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 2003; 300(1): 241-6.
226. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 2009; 8(6): 1596-605.
227. Yang QC, Zeng BF, Shi ZM, et al. Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity in human osteosarcoma. J Exp Clin Cancer Res 2006; 25(4): 593-9.
228. Newcomb EW, Ali MA, Schnee T, et al. Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro Oncol 2005; 7(3): 225-35.
229. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially downregulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007; 74(2): 191-201.
230. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a smallmolecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005; 65(19): 9047-55.
231. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG, Jr., Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA 2004; 101(48): 16768-73.
232. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer cell 2003; 3(4): 363-75.
233. Bae MK, Kim SH, Jeong JW, et al. Curcumin inhibits hypoxiainduced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006; 15(6): 1557-62.
234. Maeda M, Hasebe Y, Egawa K, Shibanuma M, Nose K. Inhibition of angiogenesis and HIF-1alpha activity by antimycin A1. Biol Pharm Bull 2006; 29(7): 1344-8.
235. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIHmediated repression of hypoxia-inducible factor-1. Blood 2008; 111(6): 3131-6.
236. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer cell 2004; 6(1): 33-43.
237. Yasui H, Ogura A, Asanuma T, et al. Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. Br J Cancer 2008; 99(9): 1442-52.
238. Zhao Q, Du J, Gu H, et al. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 2007; 34(2): 242-7.
239. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2- imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2003; 2(3): 235-43.
240. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem 2008; 283(24): 16309-19.
241. Chen P, Yin H, Wang Y, Xie L. Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1alpha in a mouse model of closed eye contact lens wear. Molecular vision 2012; 18: 864-73.
242. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105(50): 19579-86.
243. Yoshida T, Zhang H, Iwase T, Shen J, Semenza GL, Campochiaro PA. Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB Journal: official publication of the Federation of American Societies for Experimental Biology 2010; 24(6): 1759-67.
244. Wang B, Zou Y, Li H, Yan H, Pan JS, Yuan ZL. Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1alpha in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther 2005; 21(2): 107-13.
245. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007; 32(3): 517-30.
246. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxiainducible factor-1 alpha-degradative pathway. J Biol Chem 2002; 277(33): 29936-44.
247. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 2009; 69(4): 1624-32.
248. Kim JH, Yu YS, Shin JY, Lee HY, Kim KW. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy. J Cell Mol Med 2008; 12(6A): 2407-15.
249. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009; 106(7): 2353-8.
250. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a smallmolecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005; 65(19): 9047-55.